Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications. We compare the effects of these 2 drugs in schizophrenic spectrum patients of Han ethnics with neuroleptic-induced tardive dyskinesia to test the hypothesis that these two medications have different effects in improving tardive dyskinesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
• Collaborator: Department of Health
• Treatments: Antipsychotic Agents; Olanzapine; Risperidone

Criteria

Inclusion Criteria:

• Age of 18-70 y/o

• Female patients did not have pregnancy plans and must agree to use reliable pregnancy prevention methods if during childbearing age

• Meet schizophrenia, schizophreniform or schizoaffective disorder criteria of DSM-IV

• Fulfill DSM-IV neuroleptic-induced tardive dyskinesia research criteria, the severity of tardive dyskinesia was no less than moderate degree (> or =4) assessed by global impression of Extrapyramidal System Rating Scale (item 42 of ESRS)

• Patients or legal responsible people agree to join study and sign informed consent

Exclusion Criteria:

• Had other axis I diagnosis of DSM-IV

• Unstable major systemic diseases

• Had neurological disorder influenced to EPS assessment

• Substance abuse or dependence other then coffee or tobacco within 6 months before study